Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	109824
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Immune checkpoint molecules signal regulatory protein alpha in the development of hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Xue Zhang, Dong-Bo Chen, Rui Zhang, Pu Chen, Shao-Ping She, Yao Yang, Li-Ying Ren and Hong-Song Chen
Funding Agency and Grant Number	Funding Agency Grant Number National Key Sci-Tech Special Project of China 2018ZX10302207 Beijing Natural Science Foundation 7222191 Fundamental Research Funds for the Central Universities, Peking University PKU2024XGK005 Peking University Medicine Seed Fund for Interdisciplinary Research BMU2021MX007 and BMU2022MX001 Fundamental Research Funds for the Central Universities, Peking University People’s Hospital Scientific Research Development Funds RDY2020-06 and RDJ2022-14
Corresponding Author	Hong-Song Chen, Professor, Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. chenhongsong2999@163.com
Key Words	Signal regulatory protein alpha; Hepatocellular carcinoma; Immunotherapy; Immune checkpoint molecules; Immune checkpoint inhibitors
Core Tip	Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver and one of the most common malignant tumors, as well as the third leading cause of cancer-related death. In recent years, immune checkpoint inhibitors have emerged as a key strategy in cancer treatment. However, anti-programmed cell death 1/programmed death ligand 1 therapies, one of the main immunotherapeutic approaches, only elicit a response in only approximately 20% of advanced HCC. This suggests that there may be other immune checkpoints playing important roles in HCC immunotherapy. Recent studies have highlighted Signal regulatory protein alpha (SIRPα) is a phagocytic checkpoint in macrophages and other immune cells, as a promising novel therapeutic target in tumor immunotherapy. This review summarizes current progress on SIRPα in HCC and identifies key challenges for future related research.
Citation	Zhang X, Chen DB, Zhang R, Chen P, She SP, Yang Y, Ren LY, Chen HS. Immune checkpoint molecules signal regulatory protein alpha in the development of hepatocellular carcinoma. World J Gastrointest Oncol 2025; In press

Received	2025-05-26 08:36
Peer-Review Started	2025-05-26 08:36
To Make the First Decision
Return for Revision	2025-06-17 03:28
Revised	2025-06-29 02:51
Second Decision	2025-07-30 02:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-07-30 06:12
Articles in Press	2025-07-30 06:12
Publication Fee Transferred	2025-07-01 08:09
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com